Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
JuEa0T5W3LKKNk4P
